Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Prasse (Hannover, Germany), B. Jäger (Hannover, Germany), L. Plappert (Hannover, Germany), K. Kraus (Hannover, Germany), L. Wollin (Biberach, Germany). A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment. 5363

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks Source: Guideline 2015 Year: 2015 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Understanding of Pharmacokinetics and Exposure Drives use of Nintedanib as a Positive Control Reference Item in a Rat Model of Bleomycin-Induced Fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Potential benefits of Nordic Walking for Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 The Effects Of Respiratory Viruses on The Acute Pulmonary Exacerbations In Cystic Fibrosis Patients Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Effects of Long Term Exogenous Apelin Application in Experimental Pulmonary Hypertension Model Created with Monocrotaline Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020